Hereditary Angioedema (HAE) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Hereditary Angioedema (HAE) is a rare genetic disorder marked by the recurrent occurrence of transient subcutaneous and submucosal edemas, leading to swelling and abdominal pain. This condition is characterized by three distinct types, each with its prevalence and clinical manifestations. The hallmark symptoms of HAE include recurrent and unpredictable episodes of swelling in various body parts, such as the face, extremities, genitals, and gastrointestinal tract. Abdominal pain is a common manifestation and can be severe, often leading to unnecessary surgeries due to the misdiagnosis of the acute abdomen. While there is no cure for HAE, effective management strategies aim to control symptoms and reduce the frequency and severity of attacks. Medications such as C1-INH replacement therapy, bradykinin receptor antagonists, and kallikrein inhibitors have shown efficacy in treating and preventing HAE attacks. HAE is estimated to impact approximately 1 in 50,000 individuals, making it a relatively uncommon genetic disease.

·       Among the three types of HAE, Type I is the most prevalent, accounting for approximately 85 percent of cases. It is characterized by a deficiency in C1 esterase inhibitor (C1-INH), a crucial protein in regulating inflammation.

·       Type II, comprising 15 percent of cases, is also associated with a deficiency in C1-INH but differs in terms of the functionality of the available protein.

·       Type III is considered exceptionally rare and is distinguished by normal levels of C1-INH. Unlike Types I and II, the exact genetic cause of Type III HAE is not completely understood.

 

Thelansis’s “Hereditary Angioedema (HAE) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hereditary Angioedema (HAE) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Hereditary Angioedema (HAE) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Hereditary Angioedema (HAE) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Hereditary Angioedema (HAE) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Hereditary Angioedema (HAE), Hereditary Angioedema (HAE) market outlook, Hereditary Angioedema (HAE) competitive landscape, Hereditary Angioedema (HAE) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)